Skip to Content Facebook Feature Image

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Business

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI
Business

Business

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

2024-09-12 14:35 Last Updated At:14:55

SINGAPORE, Sept. 12, 2024 /PRNewswire/ -- Qritive, a leading digital pathology and AI company headquartered in Singapore, is proud to announce its collaboration with Roche, one of the largest diagnostics and life sciences companies in the world. This collaboration represents a significant milestone to advance cancer diagnostics and treatment and accelerate adoption of AI by pathologists.

With Qritive's AI-powered solutions fully integrated with Roche navify® Digital Pathology platform, pathologists can leverage AI technology to diagnose cancer more accurately and efficiently, leading to reduced time to treatment and enhanced patient outcomes. These clinically validated AI modules, designed for colon, prostate, breast, and gastric cancers, analyze whole slide images to identify and grade tumor with precision. These tools have been shown to improve pathology reporting time by up to 10-fold and reduce the risk of misdiagnosis dramatically.

As Bruno Occhipinti, CEO of Qritive, puts it, "we are truly excited to see how the integration of our AI-powered solutions within the highly performing Roche navify® Digital Pathology platform will augment pathologists' performance, enabling affordable and accurate diagnostics at scale."

Qritive's collaboration with Roche reinforces its commitment to empowering pathologists globally with state-of-the-art AI-powered solutions and alleviating the pressure on the healthcare system. By bringing its innovative AI-based pathology solutions to a broader audience, Qritive continues to play a pivotal role in the future of cancer diagnostics.

For more information about Qritive and its AI-powered solutions, please visit www.qritive.com or contact info@qritive.com.

About Qritive:

Headquartered in Singapore, with operations in the US and India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes. Qritive leverages deep learning technology to support the interpretation of pathology tests for time and resource-strapped pathologists, enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

Next Article

Gold and Fractal EMS Announce a Partnership for an American BMS

2024-09-18 02:57 Last Updated At:03:15

ANAHEIM, Calif., Sept. 18, 2024 /PRNewswire/ -- Fractal EMS Inc. ("Fractal"), a leading provider of advanced solar and storage controls, has announced a groundbreaking partnership with Gold Electronic Equipment Inc. ("Gold"), a leading high-tech company specializing in R&D, active balancing technology and manufacturing of the battery management system (BMS). A signing ceremony and celebration was held on September 9th at the RE+ clean energy conference in Anaheim, California. The new partnership will provide a cybersecure American BMS to customers worldwide ("Fractal BMS").

The Fractal BMS provides a 3-level BMS architecture (module, rack and system).  The design of the Fractal BMS has been finalized, featuring an American-sourced chip, printed circuit board assembly (PCBA), and cybersecurity, ensuring compliance with U.S. policies for sourcing and critical infrastructure protection. The Fractal BMS has the option to provide active cell balancing to maximize each battery cell's useful capacity and life.

"Other companies proposing an American BMS have not addressed the cybersecurity concerns of the BMS. Some companies are licensing a foreign BMS or only providing a top-level device, neither of which cure cybersecurity threats and vulnerabilities. We are thrilled to collaborate with Gold to bring this advanced American BMS to the market. This partnership underscores our commitment to innovation, security, and supporting American technology," said Daniel Crotzer, CEO at Fractal EMS.

Fractal BMS is scheduled for UL testing in late October 2024 and aims to become the gold standard for BESS deployments to mitigate risks associated with Foreign Entities of Concern (FEOC) and known cyber vulnerabilities in programmable devices. The American BMS will be available to battery manufacturers globally, offering a reliable and secure solution for battery management needs.

Logo - https://mma.prnasia.com/media2/2507751/fractal_ems_Logo.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2507752/Fractal_EMS_Inc.jpg?p=medium600

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Gold and Fractal EMS Announce a Partnership for an American BMS

Gold and Fractal EMS Announce a Partnership for an American BMS

Recommended Articles